Grupo Aval Acciones y Valores S.A. (0J1B)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 4.730 |
|---|---|
| 52-week range | 3.410 – 6.300 |
| Return, 1 month / 3 months | −8.5% / −6.2% |
| Return, 1 year / 3 years | – / – |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 37 |
| Volatility (1 year) | 50.1% |
| Worst drawdown (1 year) | -29.6% |
| Average daily value traded | 0.00M USD |
| Dividend yield | 0.0% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Grupo Aval Acciones y Valores is a financial holding company based in Colombia. Through its subsidiaries it offers banking services, including savings and current accounts, consumer and business lending, credit cards and payment services, to individuals and companies. It also provides pension and severance fund management and other financial services. Its banks serve customers across Colombia and in parts of Central America, and the parent company coordinates strategy and capital across its group of financial businesses.
On this site Grupo Aval Acciones y Valores S.A. appears as a stock on the London Exchange (UK), code 0J1B, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Grupo Aval Acciones y Valores S.A. (0J1B) trades on the London Exchange in UK. It last closed at USD 4.730 on 22 October 2026.
Its price-based Market X-Ray is 44 out of 100 (a weak price profile), ranking 2,428 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 67 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 3.8% | ||
| From 52-week high | -16.0% | ||
| Momentum | 46 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -6.2% | ||
| 6-month return | 2.7% | ||
| 12-month return, skipping the last month | – | ||
| Stability (higher is calmer) | 38 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 50.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -29.6% | ||
| Liquidity | 9 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M USD | ||
| Zero-volume days | 0.0% | ||
| Income | 42 · Weak | Dividend is small or irregular. | |
| Dividend yield | 0.0% | ||
| Years with dividends | 6 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
- Income: Dividend is small or irregular.
Returns
| 1 week | −3.9% |
|---|---|
| 1 month | −8.5% |
| 3 months | −6.2% |
| 6 months | +2.7% |
| 1 year | – |
| 3 years | – |
| 5 years | – |
Signals
| 50-day / 200-day average | 5.162 / 4.556 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.152 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 30 Sep 2026 | COP 0.0132 |
| 31 Aug 2026 | COP 0.0116 |
| 31 Jul 2026 | COP 0.0116 |
| 30 Jun 2026 | COP 0.0116 |
| 29 May 2026 | COP 0.0116 |
| 1 May 2026 | COP 0.0116 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.